These metabolites could have potential as lead compounds for treating metabolic syndrome, obesity, and diabetes via the inhibition of various enzymes, such as HSD, PTP1BI, α-GI, G6Pase, and DGAT. Here, DGAT1 is linked to obesity due to melanocortin 4 receptor deficiency.